- Teva Pharmaceutical Industries (NYSE:TEVA) reintroduces its generic equivalent to Depo-Provera Contraceptive Injection (medroxyprogesterone acetate injectable suspension, USP) 150 mg/mL in the U.S. for the prevention of pregnancy.
- The company says it is committed to strengthening its generic injectable business, beefing up investment in high-value products. It says it has almost 600 generic medicines available and over 100 pending first-to-file applications in the U.S.
- The U.S. market is ~$211M.
Teva to relaunch generic version of injectable contraceptive Depo-Provera in U.S.
Recommended For You
About TEVA Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
TEVA | - | - |
Teva Pharmaceutical Industries Limited |